

Robert Muga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/622790/publications.pdf>

Version: 2024-02-01

141
papers

2,727
citations

218592

26
h-index

233338

45
g-index

159
all docs

159
docs citations

159
times ranked

3615
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. <i>JAMA Psychiatry</i> , 2021, 78, 979.	6.0	244
2	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. <i>Annals of Internal Medicine</i> , 2011, 154, 509.	2.0	205
3	Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV.. <i>BMJ: British Medical Journal</i> , 1990, 301, 1130-1133.	2.4	118
4	Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters. <i>Aids</i> , 2003, 17, 353-359.	1.0	89
5	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	2.9	88
6	Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women. <i>American Journal of Epidemiology</i> , 2008, 168, 532-540.	1.6	82
7	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. <i>Gastroenterology</i> , 2013, 144, 751-760.e2.	0.6	76
8	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. <i>International Journal of Epidemiology</i> , 2002, 31, 951-958.	0.9	64
9	Acute coronary syndrome and cocaine use: 8-year prevalence and in-hospital outcomes. <i>European Heart Journal</i> , 2011, 32, 1244-1250.	1.0	53
10	Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 329-337.	0.9	53
11	Cannabinoids: from pot to lab. <i>International Journal of Medical Sciences</i> , 2018, 15, 1286-1295.	1.1	53
12	Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. <i>Aids</i> , 2001, 15, 1167-1174.	1.0	52
13	Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1293-1297.	0.5	44
14	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , 2019, 17, 4.	2.3	43
15	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	2.1	42
16	Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 944-950.	2.0	40
17	Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. <i>Drug and Alcohol Dependence</i> , 2006, 82, S29-S33.	1.6	37
18	Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. <i>World Journal of Hepatology</i> , 2016, 8, 1295.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Accuracy of Simple Biochemical Tests in Identifying Liver Fibrosis in Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 339-345.	2.4	36
20	Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. <i>Aids</i> , 2007, 21, 2521-2527.	1.0	35
21	Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. <i>Aids</i> , 2006, 20, 111-116.	1.0	32
22	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 126-133.	0.9	32
23	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
24	Impact of Medical Comorbidity and Risk of Death in 680 Patients with Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E221-7.	1.4	30
25	Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors. <i>Substance Abuse</i> , 2018, 39, 46-51.	1.1	30
26	Risk of QTc Prolongation in a Cohort of Opioid-Dependent HIV-Infected Patients on Methadone Maintenance Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1189-1194.	2.9	29
27	Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs. <i>Clinical Infectious Diseases</i> , 2007, 45, 370-376.	2.9	28
28	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 313-331.	0.8	28
29	Long-Term Mortality of Patients with an Alcohol-Related Wernicke-Korsakoff Syndrome. <i>Alcohol and Alcoholism</i> , 2017, 52, 466-471.	0.9	27
30	Risk of tuberculosis following HIV seroconversion in high-income countries. <i>Thorax</i> , 2013, 68, 207-213.	2.7	26
31	Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 121-126.	1.3	25
32	Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004-2018. <i>PLoS ONE</i> , 2021, 16, e0249864.	1.1	25
33	Cardiovascular disease burden among human immunodeficiency virus-infected individuals. <i>International Journal of Cardiology</i> , 2018, 265, 195-203.	0.8	23
34	Unhealthy Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e46810.	1.1	22
35	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 214-221.	0.9	22
36	Hyaluronic acid, transforming growth factor- β 1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 513-518.	1.0	21

#	ARTICLE	IF	CITATIONS
37	COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	1.0	21
38	Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on. <i>Aids</i> , 2006, 20, 289-291.	1.0	20
39	Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. <i>HIV Medicine</i> , 2014, 15, 203-212.	1.0	20
40	Markers of Inflammation and Mortality in a Cohort of Patients With Alcohol Dependence. <i>Medicine (United States)</i> , 2015, 94, e607.	0.4	19
41	Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 18-24.	1.0	19
42	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018, 32, 161-169.	1.0	19
43	MDMA interactions with pharmaceuticals and drugs of abuse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 357-369.	1.5	19
44	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010. <i>BMC Infectious Diseases</i> , 2013, 13, 382.	1.3	18
45	Folate deficiency in patients seeking treatment of alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2017, 180, 417-422.	1.6	18
46	A parametric survival model with an interval-censored covariate. <i>Statistics in Medicine</i> , 2004, 23, 3159-3175.	0.8	17
47	Mortality of HIV-Positive and HIV-Negative Heroin Abusers as a Function of Duration of Injecting Drug Use. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 332-338.	0.9	16
48	Estimated Liver Fibrosis and its Impact on All-Cause Mortality of HCV-Monoinfected and HCV/HIV-Coinfected Drug Users. <i>Current HIV Research</i> , 2011, 9, 256-262.	0.2	16
49	Syphilis in injecting drug users: clues for high-risk sexual behaviour in female IDUs. <i>International Journal of STD and AIDS</i> , 1997, 8, 225-228.	0.5	15
50	Key interindividual determinants in MDMA pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 183-195.	1.5	15
51	Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25732.	1.2	14
52	Effectiveness of Antiretroviral Therapy in HIV-1-Infected Active Drug Users Attended in a Drug Abuse Outpatient Treatment Facility Providing a Multidisciplinary Care Strategy. <i>Current HIV Research</i> , 2012, 10, 356-363.	0.2	13
53	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018, 32, 327-335.	1.0	13
54	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13

#	ARTICLE	IF	CITATIONS
55	Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment. <i>Aids</i> , 2021, 35, 1283-1293.	1.0	13
56	Abuse Potential of Cathinones in Humans: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1004.	1.0	13
57	Risk of HIV infection as a function of the duration of intravenous drug use: a non-parametric Bayesian approach. <i>Statistics in Medicine</i> , 2000, 19, 2641-2656.	0.8	12
58	Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit. <i>Clinical Infectious Diseases</i> , 2003, 37, S404-S409.	2.9	12
59	Prospective evaluation of latent tuberculosis with interferon- γ release assays in drug and alcohol abusers. <i>Epidemiology and Infection</i> , 2009, 137, 1342-1347.	1.0	12
60	Educational level and HIV disease progression before and after the introduction of HAART: a cohort study in 989 HIV seroconverters in Spain. <i>Sexually Transmitted Infections</i> , 2011, 87, 571-576.	0.8	12
61	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	0.9	12
62	Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte CoRIS. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 502-508.	0.3	12
63	Loss of naive T lymphocytes is associated with advanced liver fibrosis in alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108046.	1.6	12
64	Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987-2006. <i>Drug and Alcohol Dependence</i> , 2010, 110, 234-239.	1.6	10
65	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	2.1	10
66	La crisis de los opioides. <i>Medicina Clínica</i> , 2018, 151, 487-488.	0.3	10
67	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. <i>Clinical Infectious Diseases</i> , 2017, 65, 1127-1135.	2.9	10
68	Prevalence and associations of metabolic syndrome in patients with alcohol use disorder. <i>Scientific Reports</i> , 2022, 12, 2625.	1.6	10
69	Natural history of parenteral drug addicts treated in a general hospital. <i>Addiction</i> , 1990, 85, 775-778.	1.7	9
70	Epidemiology of HIV-2 infection in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 383-388.	1.3	9
71	Wide array of T-cell subpopulation alterations in patients with alcohol use disorders. <i>Drug and Alcohol Dependence</i> , 2016, 162, 124-129.	1.6	9
72	Alcoholic Liver Disease Among Patients with Wernicke Encephalopathy: A Multicenter Observational Study. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109186.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Synthetic Peptide Immunoassay in Diagnosis of Primary HIV Infection. <i>Vox Sanguinis</i> , 1990, 58, 228-230.	0.7	8
74	Multifocal splenic abscesses caused by <i>Mycobacterium tuberculosis</i> in HIV-infected drug users. <i>Aids</i> , 1991, 5, 901.	1.0	8
75	Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users. <i>Epidemiology and Infection</i> , 2002, 129, 325-333.	1.0	8
76	Effect of Liver Fibrosis on Long-Term Mortality in HIV/Hepatitis C Virus-Coinfected Individuals Who Are Evaluated to Receive Interferon Therapies in the Highly Active Antiretroviral Therapy Era. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1235-1243.	0.5	8
77	Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients. <i>Medicine (United States)</i> , 2018, 97, e12238.	0.4	8
78	Association of hyperuricemia and gamma glutamyl transferase as a marker of metabolic risk in alcohol use disorder. <i>Scientific Reports</i> , 2020, 10, 20060.	1.6	8
79	Sex-specific Associations of Alcohol Withdrawal in Patients Admitted for the Treatment of Alcohol Use Disorder. <i>Journal of Addiction Medicine</i> , 2021, 15, 68-73.	1.4	8
80	Use of Highly Active Antiretroviral Therapy is Increasing in HIV Positive Severe Drug Users. <i>Current HIV Research</i> , 2010, 8, 641-648.	0.2	8
81	Over-expression of CD8+ T-cell activation is associated with decreased CD4+ cells in patients seeking treatment of Alcohol Use Disorder. <i>Drug and Alcohol Dependence</i> , 2017, 180, 7-13.	1.6	7
82	Hepatitis C infection substantially reduces survival of alcohol-dependent patients. <i>Clinical Epidemiology</i> , 2018, Volume 10, 897-905.	1.5	7
83	Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. <i>PLoS ONE</i> , 2019, 14, e0221598.	1.1	7
84	Significance of Markers of Monocyte Activation (CD163 and sCD14) and Inflammation (IL6) in Patients Admitted for Alcohol Use Disorder Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 152-158.	1.4	7
85	Long-Term Outcomes of Patients With Cocaine Use Disorder: A 18-years Addiction Cohort Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 625610.	1.6	7
86	Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change. <i>Journal of Clinical Medicine</i> , 2022, 11, 305.	1.0	7
87	Evaluation of a commercial enzyme immunoassay for HIV screening in urine. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 831-835.	1.3	6
88	Boosted Lopinavirâ€“ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	2.9	6
89	Alcohol Consumption during Pregnancy: Analysis of Two Direct Metabolites of Ethanol in Meconium. <i>International Journal of Molecular Sciences</i> , 2016, 17, 417.	1.8	6
90	Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. <i>Drug and Alcohol Dependence</i> , 2018, 188, 180-186.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Physicians'™ opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 466-472.	1.3	6
92	Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients. <i>Open AIDS Journal</i> , 2008, 2, 82-88.	0.1	6
93	Association of Patients'™ Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. <i>Emerging Infectious Diseases</i> , 2011, 17, 1116-1119.	2.0	6
94	DSM-5 en pacientes que solicitan el primer tratamiento del trastorno por uso de alcohol. Diferencias de sexo en el estudio multicéntrico CohRTA. <i>Revista De Psicología De La Salud</i> , 2020, 32, 136.	0.2	6
95	Impact of injecting drug use on the interruption of antiretroviral therapies. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 286-287.	2.0	5
96	Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 504.	1.3	5
97	Temporal trends in the survival of drug and alcohol abusers according to the primary drug of admission to treatment in Spain. <i>Drug and Alcohol Dependence</i> , 2014, 136, 115-120.	1.6	5
98	Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2017, 11, 34-39.	1.4	5
99	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2862-2868.	1.3	5
100	Ultrasound findings of liver damage in a series of patients consecutively admitted for treatment of alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 190, 195-199.	1.6	5
101	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	1.0	5
102	Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3004-3014.	1.3	5
103	Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. <i>Scientific Reports</i> , 2021, 11, 13629.	1.6	5
104	Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. <i>World Journal of Gastroenterology</i> , 2020, 26, 5874-5883.	1.4	4
105	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 580-587.	0.3	4
106	Mortality of HIV-Positive and HIV-Negative Heroin Abusers as a Function of Duration of Injecting Drug Use. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 332-338.	0.9	3
107	The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. <i>Journal of the International AIDS Society</i> , 2014, 17, 19820.	1.2	3
108	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. <i>Medicine (United States)</i> , 2016, 95, e5133.	0.4	3

#	ARTICLE	IF	CITATIONS
109	New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona. <i>European Addiction Research</i> , 2022, 28, 323-330.	1.3	3
110	Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu010.	0.4	2
111	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 102-109.	0.9	2
112	Current Opioid Access, Use, and Problems in Central and Western European Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 478-484.	1.6	2
113	Five-Year Incidence of Hospital-Based Emergencies Related to Acute Recreational Intoxication in Minors. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 2179-2186.	1.4	2
114	Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. <i>World Journal of Gastroenterology</i> , 2021, 27, 3223-3237.	1.4	2
115	Markers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 3496.	1.0	2
116	Hepatitis C asociada al abuso de sustancias: nunca tan cerca de un tratamiento sin Interferón. <i>Revista De Psicología De La Salud</i> , 2015, 27, 141.	0.2	2
117	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. <i>Biology</i> , 2022, 11, 645.	1.3	2
118	HIV Infection in Not-at-risk Tuberculous Patients in Spain. <i>Chest</i> , 1990, 98, 1548.	0.4	1
119	Dandy Walker Syndrome and Associated Polycystic Renal Disease. <i>Nephron</i> , 1992, 60, 253-253.	0.9	1
120	Impact of Hepatitis C Virus Infection in the Liver-Related Mortality of Patients with Alcohol use Disorder. <i>Journal of Hepatology</i> , 2016, 64, S240-S241.	1.8	1
121	The opioid crisis. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 487-488.	0.1	1
122	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , 2020, 17, 45.	0.7	1
123	Cannabis use is associated with monocyte activation (sCD163) in patients admitted for alcohol use disorder treatment. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108231.	1.6	1
124	Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain. <i>Journal of the International AIDS Society</i> , 2021, 24, e25758.	1.2	1
125	Pacientes con trastorno por uso de alcohol: resultados iniciales de un registro multicéntrico en la Red de Trastornos Adictivos-RTA. <i>Estudio CohRTA. Revista De Psicología De La Salud</i> , 2018, 30, 292.	0.2	1
126	Hepatitis C associated to substance abuse: ever closer to a treatment without Interferon. <i>Revista De Psicología De La Salud</i> , 2015, 27, 141-9.	0.2	1

#	ARTICLE	IF	CITATIONS
127	HIV antigenaemia and prognosis.. BMJ: British Medical Journal, 1987, 295, 1416-1417.	2.4	0
128	Serological Markers of Human Immunodeficiency Virus Infection in African Patients with AIDS: Are They Different from Markers Found in Patients from Other Countries?. Journal of Infectious Diseases, 1988, 158, 894-894.	1.9	0
129	Non-Parenteral Transmission of Hepatitis C Virus. International Journal of STD and AIDS, 1991, 2, 449-450.	0.5	0
130	Paciente con infecci3n por el VIH en tratamiento con metadona. Trastornos Adictivos, 2005, 7, 226-234.	0.1	0
131	Paciente con abuso de alcohol, infecci3n por el VIH y hepatitis cr3nica C. Trastornos Adictivos, 2009, 11, 173-179.	0.1	0
132	28 EFFECT OF HEPATITIS C COINFECTION ON CAUSE-SPECIFIC MORTALITY FOLLOWING HIV SEROCONVERSION IN THE PRE-CART AND CART ERAS. Journal of Hepatology, 2012, 56, S13.	1.8	0
133	Prevalence and characteristics of liver disease in alcoholic patients with Wernicke encephalopathy. European Journal of Internal Medicine, 2013, 24, e258.	1.0	0
134	Meconium Biomarkers of Prenatal Alcohol Exposure. , 2019, , 585-594.		0
135	Liver Ultrasound Abnormalities in Alcohol Use Disorder. , 2019, , .		0
136	EP1.16-17 Management of Inappropriate Use of Opioids (IUO) in Patients (P) with Lung Cancer (LC). Journal of Thoracic Oncology, 2019, 14, S1070-S1071.	0.5	0
137	How well are we performing the initial assessment of HIV4positive patients? Results from a multicentre cohort in Spain. HIV Medicine, 2020, 21, 128-134.	1.0	0
138	Utilizaci3n de opioides para el dolor cr3nico no oncol3gico. Respuesta. Medicina Cl3nica, 2021, 156, 98-99.	0.3	0
139	Las otras dianas del trastorno por uso de alcohol: Afectaciones sist3micas derivadas del consumo excesivo de alcohol. Metode, 2021, , .	0.0	0
140	Use of opioids for chronic non-cancer pain. Reply. Medicina Cl3nica (English Edition), 2021, 156, 98-99.	0.1	0
141	Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex. Biomedicines, 2022, 10, 1137.	1.4	0